Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

360P Epigenetic engineering on CDX2 allows to determine the interplaying consequences with other genetic and transcriptomic events in colorectal cancer

Autor: F. Gimeno-Valiente, E. Duréndez, J. Badía, C. Martínez-Ciarpaglini, M. Iglesias, J.L. Linares, M. Huerta, D. Moro, V. Gambardella, J. Martín-Arana, T.C. Fleitas, S. Roselló Keränen, M. Cabeza Segura, B. García-Mico, P. Rentero-Garrido, D. Roda, J. Castillo, A. Cervantes, A. Calon, N. Tarazona Llavero

Publikováno v: Annals of Oncology. 33:S700

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2241cd3165e57082cac60ed4a25fea2f
https://doi.org/10.1016/j.annonc.2022.07.498

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target

Autor: T. Fleitas, C. Martínez-Ciarpaglini, Andrés Cervantes, Marisol Huerta, Josefa Castillo, Desamparados Roda, M. Cabeza-Segura, Valentina Gambardella, N. Tarazona, F. Gimeno-Valiente, Susana Roselló

Publikováno v: CANCER TREATMENT REVIEWS
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

Gastric cancer (GC) represents the fifth cause of cancer-related death worldwide. Molecular biology has become a central area of research in GC and there are currently at least three major classifications available to elucidate the mechanisms that dr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2ac8091c967c726322ec866553fb266
https://pubmed.ncbi.nlm.nih.gov/32248000

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer

Autor: C. Martínez-Ciarpaglini, T. Fleitas, Andrés Cervantes, J. M. Martín, Marisol Huerta, P. Rentero-Garrido, G. Bruixola, A. Ferrer-Martínez, Susana Roselló, Alejandro Espí, D. Moro, Francisca Carrasco, F. Gimeno-Valiente, Valentina Gambardella, S. Zuñiga, Noelia Tarazona, R. Tébar-Martínez, Josefa Castillo, Desamparados Roda, J.A. Carbonell-Asins

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

A high percentage of patients diagnosed with localized colon cancer (CC) will relapse after curative treatment. Although pathological staging currently guides our treatment decisions, there are no biomarkers determining minimal residual disease (MRD)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7179543a28db5f5e5735fbec2c9331aa
https://pubmed.ncbi.nlm.nih.gov/31562764